Company Cerus Corporation

Equities

CERS

US1570851014

Medical Equipment, Supplies & Distribution

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.89 USD +5.59% Intraday chart for Cerus Corporation -3.08% -12.50%

Business Summary

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Number of employees: 631

Sales per Business

USD in Million2022Weight2023Weight Delta
Blood Safety
100.0 %
162 100.0 % 156 100.0 % -3.51%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
59.6 %
101 62.6 % 93 59.6 % -8.05%
Europe, Middle East and Africa
23.4 %
37 22.8 % 37 23.4 % -1.22%
France
11.8 %
19 11.9 % 18 11.8 % -4.33%
North America
3.8 %
3 1.6 % 6 3.8 % +130.19%
Other
1.4 %
2 1.1 % 2 1.4 % +22.50%

Managers

Managers TitleAgeSince
Founder 80 91-09-18
Chief Executive Officer 57 94-12-31
Director of Finance/CFO 52 05-12-31
Chief Operating Officer 49 16-08-28
Chief Tech/Sci/R&D Officer 74 07-12-31
Chief Administrative Officer - 91-12-31
Chief Tech/Sci/R&D Officer 64 15-07-12
Investor Relations Contact - -
Human Resources Officer - 23-09-26
Corporate Officer/Principal - 06-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 19-03-03
Chief Executive Officer 57 94-12-31
Founder 80 91-09-18
Director/Board Member 70 14-03-23
Director/Board Member 64 18-10-08
Chairman 61 11-05-31
Director/Board Member 62 18-09-04
Director/Board Member 72 07-10-24
Director/Board Member 37 21-08-03
Director/Board Member 63 22-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 181,282,725 174,464,866 ( 96.24 %) 0 96.24 %

Shareholders

NameEquities%Valuation
ARK Investment Management LLC
11.54 %
20,914,326 11.54 % 46 M $
Baker Bros. Advisors LP
10.75 %
19,477,339 10.75 % 42 M $
BlackRock Advisors LLC
7.256 %
13,147,884 7.256 % 29 M $
Vanguard Fiduciary Trust Co.
5.447 %
9,870,671 5.447 % 22 M $
PRIMECAP Management Co.
4.753 %
8,613,000 4.753 % 19 M $
Nikko Asset Management Americas, Inc.
4.177 %
7,568,071 4.177 % 16 M $
Senvest Management LLC
3.634 %
6,583,826 3.634 % 14 M $
Wasatch Advisors, Inc.
3.604 %
6,530,019 3.604 % 14 M $
Geode Capital Management LLC
2.215 %
4,012,720 2.215 % 9 M $
3,517,032 1.941 % 8 M $

Company contact information

Cerus Corp.

1220 Concord Avenue Suite 600

94520, Concord

+925 288 6000

http://www.cerus.com
address Cerus Corporation(CERS)